Monte Rosa Therapeutics (GLUE) Current Deferred Revenue (2023 - 2026)

Monte Rosa Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $33.1 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 1.49% year-over-year to $33.1 million; the TTM figure through Mar 2026 stood at $33.1 million (up 1.49% YoY), while the FY2025 annual figure was $111.3 million, up 589.49% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $33.1 million, down from $111.3 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $111.9 million in Q3 2025, with the low at $16.1 million in Q4 2024.
• The 4-year median for Current Deferred Revenue is $26.5 million (2024), against an average of $41.4 million.
• Peak annual rise in Current Deferred Revenue reached 589.49% in 2025, while the deepest fall reached 45.2% in 2025.
• Monte Rosa Therapeutics' Current Deferred Revenue stood at $17.7 million in 2023, then fell by 8.66% to $16.1 million in 2024, then jumped by 589.49% to $111.3 million in 2025, then sank by 70.31% to $33.1 million in 2026.
• Business Quant data shows GLUE's Current Deferred Revenue at $33.1 million in Q1 2026, $111.3 million in Q4 2025, and $111.9 million in Q3 2025.